Two recent drug approvals changed the game for ocular surface disease: Xdemvy (lotilaner ophthalmic solution) 0.25 percent (Tarsus Pharmaceuticals) for Demodex blepharitis, and Miebo (perfluorohexyloctane ophthalmic solution) from Bausch + Lomb and Novaliq for evaporative dry eye disease.
On today’s podcast, two ocular surface disease experts talk about these and other developments related to dry eye.
Our guests:
Dr. Periman was an investigator in the Xdemvy clinical trials, and Dr. Nijm was involved in an extended observational study.
“Before Xdemvy, patients’ options were limited,” Dr. Nijm told host Carey Powers. “When treated with Xdemvy, at one year, about 60 percent of patients still had clearance of Demodex.”
Periman noted that during clinical trials, within a week or two she noticed “impressive improvements” in redness, reduction of collarette, and mite load in patients treated with Xdemvy. She also said the drug was “extremely well tolerated.”
Miebo, a product designed to prevent excessive tear evaporation in patients with dry eye, is also expected to bring relief to a wide number of people. Dr. Periman sees Miebo as a “rapid go-to” for patients with an evaporative component, as it will potentially allow the ocular surface to protect the cornea as it’s supposed to.
These two products alone will help make ocular surface diseases easier to manage; however, other exciting innovations emerging later this year could liven up the playing field.
Listen to the podcast today to discover:
[Listen Now]
Resources
Lisa Nijm, MD, JD: warrenvilleeyecare.com
Laura Periman, MD: dryeyemaster.com/about-laura-periman
Carey Powers: ois.net/carey-powers